Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PPD Stock Summary
In the News
PPD, Inc. (PPD) CEO David Simmons on Q3 2021 Results - Earnings Call Transcript
PPD, Inc. (PPD) CEO David Simmons on Q3 2021 Results - Earnings Call Transcript
PPD, Inc. (PPD) Tops Q3 Earnings and Revenue Estimates
PPD, Inc. (PPD) delivered earnings and revenue surprises of 16.22% and 7.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
PPD Announces Third Quarter 2021 Earnings Conference Call
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Third Quarter 2021 Earnings Conference Call
PPD, Inc. (PPD) CEO David Simmons on Q2 2021 Results - Earnings Call Transcript
PPD, Inc. (PPD) CEO David Simmons on Q2 2021 Results - Earnings Call Transcript
PPD, Inc. (PPD) Surpasses Q2 Earnings and Revenue Estimates
PPD, Inc. (PPD) delivered earnings and revenue surprises of 14.71% and 17.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
PPD Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of PPD, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PPD
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of PPD, Inc. (NASDAQ: PPD) to Thermo Fisher Scientific Inc. for $47.50 per share is fair to PPD shareholders. Halper Sadeh encourages PPD shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether PPD and its board of
PPD, Inc. (PPD) Soars 6.5%: Is Further Upside Left in the Stock?
PPD, Inc. (PPD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Midday Market Update: The 10 Most Active Stocks Today
It's time for the midday market update for Thursday as several companies are on the move with various increases and decreases. The post Midday Market Update: The 10 Most Active Stocks Today appeared first on InvestorPlace.
Medable Secures Another $78 Million Funding to Fuel Digital Innovation for Patient-Centered Drug Development
PALO ALTO, Calif.--(BUSINESS WIRE)-- #biotech--Medable announced $78 million in new funding to fuel advances in the delivery of decentralized clinical trials and patient-centered research.
Thermo Fisher to buy PPD, in a cash deal valued at $17.4 billion including debt
Shares of PPD Inc. rallied 7.3% in premarket trading Thursday, after Thermo Fisher Scientific Inc. confirmed an agreement to buy the pharmaceutical-testing company in a cash deal valued at $17.4 billion, including $3.5 billion in debt. Thermo Fisher shares gained 3.1% ahead of the open.
PPD Financial details
PPD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 8.26 | 9.23 | 11.56 | 11.88 | 13.5 | |
Net income per share | 0.56 | 0.91 | 0.32 | 0.14 | 0.44 | |
Operating cash flow per share | 1.26 | 1.1 | 1.31 | 1.28 | 0.72 | |
Free cash flow per share | 0.98 | 0.78 | 0.95 | 0.9 | 0.25 | |
Cash per share | 0 | 1.29 | 1.71 | 1.02 | 2.22 | |
Book value per share | 0 | -4.59 | -4.69 | -7.95 | -2.15 | |
Tangible book value per share | 0 | -13.85 | -13.18 | -15.77 | -9.56 | |
Share holders equity per share | 0 | -4.59 | -4.69 | -7.95 | -2.15 | |
Interest debt per share | 0 | 15.51 | 15.49 | 17.44 | 13.47 | |
Market cap | 9.73B | 9.75B | 9.73B | 10.18B | 11.86B | |
Enterprise value | 0 | 14.15B | 13.97B | 15.68B | 15.55B | |
P/E ratio | 53.12 | 32.94 | 93.38 | 212.93 | 77.19 | |
Price to sales ratio | 3.63 | 3.25 | 2.6 | 2.53 | 2.53 | |
POCF ratio | 23.84 | 27.16 | 22.98 | 23.52 | 47.2 | |
PFCF ratio | 30.61 | 38.4 | 31.66 | 33.17 | 134.81 | |
P/B Ratio | 0 | -6.54 | -6.39 | -3.77 | -15.89 | |
PTB ratio | 0 | -6.54 | -6.39 | -3.77 | -15.89 | |
EV to sales | 0 | 4.72 | 3.73 | 3.89 | 3.32 | |
Enterprise value over EBITDA | 0 | 25.99 | 20.97 | 25 | 23.26 | |
EV to operating cash flow | 0 | 39.42 | 33 | 36.22 | 61.86 | |
EV to free cash flow | 0 | 55.74 | 45.47 | 51.08 | 176.67 | |
Earnings yield | 0.02 | 0.03 | 0.01 | 0 | 0.01 | |
Free cash flow yield | 0.03 | 0.03 | 0.03 | 0.03 | 0.01 | |
Debt to equity | 0 | -3.21 | -3.13 | -2.08 | -5.96 | |
Debt to assets | 0 | 0.88 | 0.87 | 1.01 | 0.71 | |
Net debt to EBITDA | 0 | 8.08 | 6.37 | 8.76 | 5.51 | |
Current ratio | 0 | 1.02 | 1.08 | 0.86 | 1.12 | |
Interest coverage | 1.55 | 1.03 | 1.53 | 1.34 | 2.35 | |
Income quality | 2.23 | 1.21 | 4.06 | 9.05 | 1.64 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.02 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0.55 | 0.5 | 0.48 | 0.41 | |
Capex to operating cash flow | -0.22 | -0.29 | -0.27 | -0.29 | -0.65 | |
Capex to revenue | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | |
Capex to depreciation | -0.35 | -0.38 | -0.45 | -0.48 | -0.59 | |
Stock based compensation to revenue | 0 | 0.02 | 0 | 0 | 0 | |
Graham number | 0 | 9.7 | 5.83 | 5.02 | 4.63 | |
ROIC | 0 | 1.45 | 0.09 | 0.13 | 0.12 | |
Return on tangible assets | 0 | 0.12 | 0.04 | 0.02 | 0.04 | |
Graham Net | 0 | -17.39 | -16.96 | -20.31 | -14.56 | |
Working capital | 0 | 30.35M | 137.46M | -288.06M | 268.64M | |
Tangible asset value | 0 | -4.5B | -4.27B | -5.35B | -3.32B | |
Net current asset value | 0 | -5.27B | -5.08B | -6.44B | -4.49B | |
Invested capital | 0 | -3.21 | -3.13 | -2.08 | -5.96 | |
Average receivables | 0 | 0 | 1.21B | 1.32B | 1.49B | |
Average payables | 0 | 0 | 92.85M | 109.54M | 153.2M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 140.19 | 124.31 | 122.61 | 127.25 | |
Days payables outstanding | 0 | 22.97 | 14.28 | 19.71 | 22.33 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 2.6 | 2.94 | 2.98 | 2.87 | |
Payables turnover | 0 | 15.89 | 25.56 | 18.52 | 16.35 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | -0.2 | -0.07 | -0.02 | -0.21 | |
Capex per share | -0.28 | -0.32 | -0.36 | -0.37 | -0.47 |
Quarterly Fundamentals Overview
Last date of statement is 2021-09-30 for Q3
Metric | History | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.54 | 3.9 | 3.94 | 4.49 | 4.44 | |
Net income per share | 0.02 | 0.29 | 0.13 | 0.15 | 0.48 | |
Operating cash flow per share | 0.39 | -0.05 | 0.42 | 0.42 | 0.83 | |
Free cash flow per share | 0.26 | -0.18 | 0.35 | 0.34 | 0.73 | |
Cash per share | 2.3 | 2.2 | 2.36 | 2.7 | 3.34 | |
Book value per share | -2.73 | -2.13 | -1.83 | -1.55 | -1.21 | |
Tangible book value per share | -10.02 | -9.48 | -9.04 | -8.62 | -8.09 | |
Share holders equity per share | -2.73 | -2.13 | -1.83 | -1.55 | -1.21 | |
Interest debt per share | 12.92 | 12.86 | 12.78 | 12.68 | 12.7 | |
Market cap | 12.89B | 11.97B | 13.24B | 16.18B | 16.44B | |
Enterprise value | 16.54B | 15.66B | 16.83B | 19.64B | 19.69B | |
P/E ratio | 428.95 | 29.9 | 72.13 | 79.32 | 24.61 | |
Price to sales ratio | 10.45 | 8.78 | 9.6 | 10.27 | 10.54 | |
POCF ratio | 93.65 | -698.76 | 89.36 | 110.18 | 56.44 | |
PFCF ratio | 143.62 | -186.93 | 109.1 | 133.98 | 64.22 | |
P/B Ratio | -13.56 | -16.04 | -20.68 | -29.82 | -38.74 | |
PTB ratio | -13.56 | -16.04 | -20.68 | -29.82 | -38.74 | |
EV to sales | 13.41 | 11.48 | 12.21 | 12.47 | 12.61 | |
Enterprise value over EBITDA | 117.9 | 71.2 | 92.62 | 96.39 | 60.07 | |
EV to operating cash flow | 120.15 | -913.77 | 113.63 | 133.72 | 67.57 | |
EV to free cash flow | 184.27 | -244.44 | 138.74 | 162.6 | 76.88 | |
Earnings yield | 0 | 0.01 | 0 | 0 | 0.01 | |
Free cash flow yield | 0.01 | -0.01 | 0.01 | 0.01 | 0.02 | |
Debt to equity | -4.68 | -5.96 | -6.91 | -8.12 | -10.4 | |
Debt to assets | 0.74 | 0.71 | 0.68 | 0.65 | 0.63 | |
Net debt to EBITDA | 26.01 | 16.75 | 19.79 | 16.97 | 9.89 | |
Current ratio | 1.09 | 1.12 | 1.16 | 1.19 | 1.23 | |
Interest coverage | 2.86 | 3.4 | 3.17 | 3.22 | 4.04 | |
Income quality | 18.32 | -0.17 | 3.23 | 2.88 | 1.74 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.42 | 0.41 | 0.39 | 0.37 | 0.34 | |
Capex to operating cash flow | -0.35 | 2.74 | -0.18 | -0.18 | -0.12 | |
Capex to revenue | -0.04 | -0.03 | -0.02 | -0.02 | -0.02 | |
Capex to depreciation | -0.67 | -0.65 | -0.37 | -0.33 | -0.48 | |
Stock based compensation to revenue | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Graham number | 1.15 | 3.71 | 2.32 | 2.25 | 3.6 | |
ROIC | 0.02 | 0.04 | 0.03 | 0.02 | 0.04 | |
Return on tangible assets | 0 | 0.03 | 0.01 | 0.01 | 0.04 | |
Graham Net | -14.55 | -14.43 | -13.97 | -13.71 | -13.42 | |
Working capital | 203.03M | 268.64M | 386.72M | 501.15M | 630.51M | |
Tangible asset value | -3.49B | -3.32B | -3.16B | -3.03B | -2.84B | |
Net current asset value | -4.58B | -4.49B | -4.27B | -4.14B | -4.02B | |
Invested capital | -4.68 | -5.96 | -6.91 | -8.12 | -10.4 | |
Average receivables | 1.46B | 1.56B | 1.75B | 1.95B | 2.06B | |
Average payables | 122.74M | 148.18M | 173.71M | 180.81M | 186.02M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 108.64 | 107.67 | 121.44 | 116.37 | 120.17 | |
Days payables outstanding | 14.04 | 18.68 | 17.94 | 16.87 | 16.96 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.83 | 0.84 | 0.74 | 0.77 | 0.75 | |
Payables turnover | 6.41 | 4.82 | 5.02 | 5.34 | 5.31 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.01 | -0.13 | -0.07 | -0.09 | -0.39 | |
Capex per share | -0.14 | -0.13 | -0.08 | -0.07 | -0.1 |
PPD Frequently Asked Questions
What is PPD, Inc. stock symbol ?
PPD, Inc. is a US stock , located in Wilmington of North carolina and trading under the symbol PPD
Is PPD, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $40. The lowest prediction is $40 and the highest is $40
What is PPD stock prediction ?
What is PPD, Inc. stock quote today ?
PPD, Inc. stock price is $47.28 today.
Is PPD, Inc. stock public?
Yes, PPD, Inc. is a publicly traded company.